Efficacy of Prostate-Specific Antigen Screening: Use of Regression Discontinuity in the PLCO Cancer Screening Trial.
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York.
Jonathan
J
Shoag
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York.
Joshua
J
Halpern
Department of Urology, Massachusetts General Hospital, Boston.
Brian
B
Eisner
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York.
Richard
R
Lee
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York.
Sameer
S
Mittal
Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York.
Christopher E
CE
Barbieri
Department of Public Policy, Harvard Kennedy School, Cambridge, Massachusetts.
Daniel
D
Shoag
D001706:Biopsy; D003627:Data Interpretation, Statistical; D051517:Digital Rectal Examination; D055088:Early Detection of Cancer / Q000379:methods*; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D008297:Male; D011237:Predictive Value of Tests; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology; D012044:Regression Analysis; D013997:Time Factors
C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen